The Viral/Molecular Core (Core D) provides reagents, facilities, lab services, consultation &training in support of innovative, multidisciplinary and translational HIV/AIDS research on the Penn/CHOP/Wistar campus with the broad goal of advancing collaborative research in the pathogenesis, treatment, and prevention of HIV/AIDS, serving CFAR investigators from multiple programs. The specific Core activities supporting this goal are to provide: ? Virology services including a repository of HIV-1 prototype, primary and mutant strains;virus isolation from patient samples;amplification of virus working stocks;structurally intact inactivated virions;HIV p24 and SIV p27 ELISA assay;and other viral services. ? Molecular services including support for realtime qPCR along with reagents, optimized primer-probe sets and custom primer/probe development;viral genotyping or cloning from clinical specimens;molecular virology support for translational research programs;and in the next cycle a new high density pyrosequencing service. ? Education, training, consultation and leadership in molecular virology activities including training in BSL3 practices for CFAR members lab personnel;training and consultation in virological and molecular techniques for CFAR investigator personnel;facilitating the dissemination and adoption of new technologies; and collaboration with and support of other Cores and campus programs in their HIV/AIDS research-related educational efforts. During the current funding cycle the Core provided support to 46 CFAR investigators, contributing to novel gene therapy approaches to HIV infection;better understanding of integration and establishment of latency;new approaches to vaccine design;advances in viral entry and resistance to entry inhibitors;effects of neuroimmune mediators &drugs of abuse;HIV neuropathogenesis;and other areas. The V/M Core has evolved significantly over the past 9 years in response to CFAR member needs and user feedback, levels of utilization, and internal &external advisory input, and collaborates closely with other CFAR Cores in support of these goals. The Core has been directed since its inception by Drs. Ronald Collman (director) and Luis Montaner (co-director) and, going forward, will be joined by Dr. F. (Rick) Bushman (co-director) to supervise the introduction and dissemination of new molecular sequencing technologies to CFAR investigators.

Public Health Relevance

The Viral/Molecular Core provides laboratory services, reagents, facilities, training and support in the area of fundamental virology and molecular biology in order to enhance the ability of investigators on campus to carry out innovative research on the pathogenesis, treatment and prevention of HIV/AIDS utilizing state-ofthe art technology, optimal virus strains, maximal efficiency and the highest level of biosafety.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI045008-13
Application #
8293245
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
Budget Start
2011-07-01
Budget End
2012-06-30
Support Year
13
Fiscal Year
2011
Total Cost
$309,296
Indirect Cost
Name
University of Pennsylvania
Department
Type
DUNS #
042250712
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Salantes, D Brenda; Zheng, Yu; Mampe, Felicity et al. (2018) HIV-1 latent reservoir size and diversity are stable following brief treatment interruption. J Clin Invest 128:3102-3115
Hogan, Michael J; Conde-Motter, Angela; Jordan, Andrea P O et al. (2018) Increased surface expression of HIV-1 envelope is associated with improved antibody response in vaccinia prime/protein boost immunization. Virology 514:106-117
Tawe, Leabaneng; Grover, Surbhi; Narasimhamurthy, Mohan et al. (2018) Molecular detection of human papillomavirus (HPV) in highly fragmented DNA from cervical cancer biopsies using double-nested PCR. MethodsX 5:569-578
Lazar, Nellie Riendeau; Salas-Humara, Caroline; Wood, Sarah M et al. (2018) Missed Opportunities for HIV Screening Among a Cohort of Adolescents With Recently Diagnosed HIV Infection in a Large Pediatric Hospital Care Network. J Adolesc Health 63:799-802
Gowda, Charitha; Lott, Stephen; Grigorian, Matthew et al. (2018) Absolute Insurer Denial of Direct-Acting Antiviral Therapy for Hepatitis C: A National Specialty Pharmacy Cohort Study. Open Forum Infect Dis 5:ofy076
Krump, Nathan A; Liu, Wei; You, Jianxin (2018) Mechanisms of persistence by small DNA tumor viruses. Curr Opin Virol 32:71-79
Coviello, D M; Lovato, R; Apostol, K et al. (2018) Prevalence of HIV Viral Load Suppression Among Psychiatric Inpatients with Comorbid Substance Use Disorders. Community Ment Health J :
Clarke, Erik L; Connell, A Jesse; Six, Emmanuelle et al. (2018) T cell dynamics and response of the microbiota after gene therapy to treat X-linked severe combined immunodeficiency. Genome Med 10:70
Martei, Yehoda M; Pace, Lydia E; Brock, Jane E et al. (2018) Breast Cancer in Low- and Middle-Income Countries: Why We Need Pathology Capability to Solve This Challenge. Clin Lab Med 38:161-173
Ojikutu, Bisola O; Bogart, Laura M; Higgins-Biddle, Molly et al. (2018) Facilitators and Barriers to Pre-Exposure Prophylaxis (PrEP) Use Among Black Individuals in the United States: Results from the National Survey on HIV in the Black Community (NSHBC). AIDS Behav 22:3576-3587

Showing the most recent 10 out of 775 publications